title: Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome.
abstract: Restricting transgene expression to maturing erythroid cells can reduce the risk for activating oncogenes in hematopoietic stem cells (HSCs) and their progeny, yet take advantage of their robust protein synthesis machinery for high-level protein production. This study sought to evaluate the feasibility and efficacy of reprogramming erythroid cells for production of a lysosomal enzyme, alpha-L-iduronidase (IDUA). An erythroid-specific hybrid promoter provided inducible IDUA expression and release during in vitro erythroid differentiation in murine erythroleukemia cells, resulting in phenotypical cross-correction in an enzyme-deficient lymphoblastoid cell line derived from patients with mucopolysaccharidosis type I (MPS I). Stable and higher than normal plasma IDUA levels were achieved in vivo in primary and secondary MPS I chimeras for at least 9 months after transplantation of HSCs transduced with the erythroid-specific IDUA-containing lentiviral vector (LV). Moreover, long-term metabolic correction was demonstrated by normalized urinary glycosaminoglycan accumulation in all treated MPS I mice. Complete normalization of tissue pathology was observed in heart, liver, and spleen. Notably, neurological function and brain pathology were significantly improved in MPS I mice by erythroid-derived, higher than normal peripheral IDUA protein. These data demonstrate that late-stage erythroid cells, transduced with a tissue-specific LV, can deliver a lysosomal enzyme continuously at supraphysiological levels to the bloodstream and can correct the disease phenotype in both viscera and CNS of MPS I mice. This approach provides a paradigm for the utilization of RBC precursors as a depot for efficient and potentially safer systemic delivery of nonsecreted proteins by ex vivo HSC gene transfer.
authors.affiliation: Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
authors.forename: Daren
authors.initials: D
authors.lastname: Wang
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.forename: Theodosia A
authors.initials: TA
authors.lastname: Kalfa
authors.forename: Gregory
authors.initials: G
authors.lastname: Grabowski
authors.forename: Stella
authors.initials: S
authors.lastname: Davies
authors.forename: Punam
authors.initials: P
authors.lastname: Malik
authors.forename: Dao
authors.initials: D
authors.lastname: Pan
mesh_terms: D000818:Animals; D002454:Cell Differentiation / Q000502:physiology; D002490:Central Nervous System / Q000002:abnormalities / Q000473:pathology / Q000502:physiology*; D002648:Child; D041905:Erythroid Cells / Q000166:cytology / Q000378:metabolism*; D015316:Genetic Therapy / Q000379:methods; D006025:Glycosaminoglycans / Q000652:urine; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000502:physiology; D006801:Humans; D007068:Iduronidase / Q000235:genetics / Q000378:metabolism*; D008247:Lysosomes / Q000201:enzymology*; D051379:Mice; D008059:Mucopolysaccharidosis I / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D011401:Promoter Regions, Genetic; D019076:Transgenes; D014781:Viscera / Q000378:metabolism*
chemical_list: D006025:Glycosaminoglycans; D007068:Iduronidase